|
Asp
|
asp
|
ASP-YL9 peptide (89YLYNSLLQL97) induces release of IL-2, IFN-gamma, TNF-alpha, or MIP-1beta in antigen-specific CD8+ T-cells |
PubMed
|
|
asp
|
The expression of ASP is upregulated by TNF-alpha in Molt-4 cells in a dose-dependent manner |
PubMed
|
|
Envelope surface glycoprotein gp120
|
env
|
HIV-1 IIIB Env (gp120) upregulates production of TNF (TNF-a), IL-17A, CCL2 (MCP1), CCL5 (RANTES), IL6, IL10, CXCL8 (IL8), CXCL1 (GRO-a), and CCL1 (I309) in stimulated monocyte derived macrophages |
PubMed
|
|
env
|
HIV-1 JRFL Env (gp120) upregulates TNFa in ARPE-19 cells |
PubMed
|
|
env
|
Curcumin, a potent and safe anti-inflammatory compound, inhibits HIV-1 gp120-mediated upregulation of the proinflammatory cytokines TNF-alpha and IL-6, and the chemokines IL-8, RANTES, and IP-10 in primary human genital epithelial cells |
PubMed
|
|
env
|
Cytokines induced in vitro by HIV-1 gp120 in normal peripheral blood mononuclear cells (PBMC) include interferon-alpha (IFN-alpha) and IFN-gamma, tumor necrosis factor-alpha (TNF-alpha), IL-6, IL-10, IL-1 alpha and IL-1 beta |
PubMed
|
|
env
|
HIV-1 gp120 stimulates human cells to release TNF-alpha, IL-1 beta, IL-6, and granulocyte-macrophage-CSF, and this effect can be blocked with soluble CD4 |
PubMed
|
|
env
|
Co-treatment with HIV-1 gp120, TNF-alpha, and ZVAD induces necroptosis in HT-29 cells |
PubMed
|
|
env
|
B cells from peripheral blood and lymph nodes of HIV-infected individuals secrete significant levels of TNF-alpha in the presence of HIV-1 gp120 |
PubMed
|
|
env
|
HIV-1 gp120-treated vaginal epithelial cells show upregulation of tumor necrosis factor (TNF, TNF-alpha) expression as compared to untreated control |
PubMed
|
|
env
|
The binding of soluble HIV-1 gp120 to TLR2 or TLR4 results in upregulation of the TNF-alpha and IL-8 production through NF-kappaB activation |
PubMed
|
|
env
|
HIV-1 gp120 enhances TNF-alpha-induced VCAM-1 gene expression in coronary macrovascular endothelial cells |
PubMed
|
|
env
|
HIV-1 gp120 inhibits CpG-A-induced secretion of TNF-alpha, IL-6, and IP-10 proteins in plasmacytoid dendritic cells and PBMCs |
PubMed
|
|
env
|
NK cells that respond with IFN-gamma and TNF-alpha cytokine production to HIV-1 gp120 peptides have reduced CD16 and NKp46 expression and have increased levels of CD57 |
PubMed
|
|
env
|
Frequent IFN-gamma and TNF-alpha NK cell responses to HIV-1 gp120 are dominant during chronic HIV-1 infection |
PubMed
|
|
env
|
HIV-1 gp120 induces human glial cells to release more TNF-alpha and IL-1beta than untreated cells |
PubMed
|
|
env
|
Inhibition of NRF2 by siRNA results in increased NOX2, NFkappaB (p65/p50), TNF-alpha, and MMP-9 proteins in astrocytes exposed to HIV-1 gp120 |
PubMed
|
|
env
|
HIV-1 gp120 stimulates the release of TNF-alpha from TPA-differentiated HL-60 cells; treatment with TNF-alpha neutralizing antibody and anti-TNF-alpha receptor type II (TNFR-II) antibody, inhibits gp120-induced upregulation of mu opioid receptor |
PubMed
|
|
env
|
HIV-1 gp120 inhibits TLR9-mediated upregulation of CD83 and the secretion of inflammatory cytokines TNF-alpha and IL-6, and chemokine IP10 in plasmacytoid dendritic cells (pDC) |
PubMed
|
|
env
|
HIV-1 gp120 triggers apoptosis in primary osteoblasts and osteoblast-derived cell lines (HOBIT) through TNFalpha activation |
PubMed
|
|
env
|
HIV gp120 and TNF-alpha synergistically reduce endothelial nitric oxide synthase (eNOS) expression and cause endothelial dysfunction via ICAM-1 |
PubMed
|
|
env
|
Stimulation of human monocyte-derived macrophages with HIV-1 gp120 results in the CCR5-mediated activation of Lyn and the concomitant Lyn-dependent activation of the mitogen-activated protein (MAP) kinase ERK-1/2, which leads to production of TNF-alpha |
PubMed
|
|
env
|
Genistein, tyrosine kinase inhibitor, suppresses HIV-1 gp120-induced TNF-alpha secretion by primary macrophage |
PubMed
|
|
env
|
In CD4-positive Jurkat cells, HIV-1 gp120 enhances TNF-induced NF-kappa B activation |
PubMed
|
|
env
|
Treatment of HIV-1-infected monocytes with TNF-alpha increases the sensitivity of the interaction of the HIV-1 antigen gp120 with cytotoxic sera from HIV-1 infected individuals |
PubMed
|
|
env
|
Enhanced TNF-alpha responses are observed when peripheral blood mononuclear cells (PBMCs) are costimulated with HIV-1 gp120 and mannose-binding lectin (MBL) |
PubMed
|
|
env
|
CD4 downregulation by the treatment of macrophages with HIV-1 gp120 is mediated through the induction of endogenous TNF-alpha |
PubMed
|
|
env
|
Apoptosis of CD8+ cells is mediated by the interaction between TNF-alpha bound to the membrane of macrophages (mbTNF) and a receptor on CD8+ T cells (TNF-receptor II, or TNFRII), which is upregulated by treatment with recombinant HIV-1 gp120 or SDF-1 |
PubMed
|
|
env
|
Pretreatment of HIV-1 infected cells with TNF alpha augments syncytia formation mediated by the interaction of HIV-1 gp120 with cell surface CD4 molecules |
PubMed
|
|
env
|
Exposure of macrophages to purified CCR5- or CXCR4-tropic HIV-1 envelope glycoprotein gp120 induces secretion of high levels of macrophage inflammatory protein 1alpha (MIP-1alpha), MIP-1beta, RANTES, and tumor necrosis factor alpha |
PubMed
|
|
env
|
HIV-1 gp120 partially inhibits the negative beta-adrenergic modulation of lipopolysaccharide-induced production of tumor necrosis factor alpha in microglial cells |
PubMed
|
|
Envelope surface glycoprotein gp160, precursor
|
env
|
HIV-1 gp160 inhibits lipoteichoic acid (LTA)-mediated TNF secretion from RAW cells |
PubMed
|
|
env
|
Pretreatment of CD4+ T cells with HIV-1 gp160 results in marked inhibition of TNF-alpha secretion |
PubMed
|
|
env
|
Pretreatment of cells with HIV-1 gp160 results in marked inhibition of tyrosine phosphorylation of p59(fyn), PLC-gamma1, ras activation, and TNF-alpha secretion in anti-CD3 mAb activated CD4+ T cells |
PubMed
|
|
env
|
HIV-1 gp160-induced apoptosis is affected in part by the release of TNF-alpha and is associated with attenuated Bcl-2 mRNA expression |
PubMed
|
|
Envelope transmembrane glycoprotein gp41
|
env
|
Exposure of TZM-bl-2 cells to HIV gp41 increases TNF (TNF-alpha) mRNA |
PubMed
|
|
env
|
The HIV-1 gp41 transmembrane domain inhibits TLR2-induced activation of ERK1/2, and secretion of TNF-alpha, MCP-1, and IL-6 |
PubMed
|
|
env
|
HIV-1 gp41 stimulates microglial cell production of cytokines (TNF-alpha, IL-1beta, and IL-6) and chemokines (RANTES and MIP-1alpha) |
PubMed
|
|
env
|
HIV-1 gp41 or gp120 synthetic peptides induce the production of interleukin (IL)-1 and tumor necrosis factor (TNF); in contrast, gp41 or gp120 synthetic peptides are able to depress the production of interferon (IFN)-alpha, IFN-gamma, and IL-2 |
PubMed
|
|
Nef
|
nef
|
HIV-1 infected clinical samples have plasma extracellular vesicles that contain ADAM10, ADAM17, and TNF when compared to healthy donors |
PubMed
|
|
nef
|
HIV-1 and SIVcpz Nef proteins enhance TNF-alpha, IKK-beta, and RelA/p65-induced NF-kappaB activation in 293T cells |
PubMed
|
|
nef
|
The activating effect of exogenous HIV-1 Nef on PBMC proliferation and on monocyte-derived macrophages is associated with an upregulation of TNF-alpha and IL-6 production |
PubMed
|
|
nef
|
HIV-1 Nef expression by immature human and macaque dendritic cells (DCs) upregulates IL-6, IL-12, TNF-alpha, CXCL8, CCL3, and CCL4 release, but without upregulating co-stimulatory and other molecules characteristic of mature DCs |
PubMed
|
|
nef
|
Primary quiescent CD4+ T lymphocytes release both TNF-alpha and IL-2 in response to the treatment with exosomes from cells infected by HIV-1, but not by delta-Nef HIV-1 or Nef (62EEEE/AAAA65) HIV-1 strains |
PubMed
|
|
nef
|
The proportion of HIV-1 Nef-specific CD8+ T cells endowed with TNF-alpha+, IFN-gamma+, CD107A+, and MIP-1beta+ is significantly higher in patients with the lowest virus set point than those with the highest virus set point |
PubMed
|
|
nef
|
HIV-1 Nef inhibits TNF-alpha release and enhances the expression of MKP-1 in human macrophages. TNF-alpha release is also inhibited in macrophages from HIV-infected patients |
PubMed
|
|
nef
|
HIV-1 myristoylated Nef-induced TNF-alpha release leads to downregulation of CD36 expression by myristoylated Nef in monocyte-derived macrophages |
PubMed
|
|
nef
|
HIV-1 Nef-mediated activation of TACE cleaves pro-TNF alpha in endosomal compartments |
PubMed
|
|
nef
|
HIV-1 Nef inhibits IFN-gamm-induced apoptosis and upregulates TNF-alpha, IL-6 and MIP-3alpha production by Caco-2 cells while downregulating IL-10 production |
PubMed
|
|
nef
|
Both the myristoylation site and the acidic cluster in HIV-1 Nef are required for the activation of NF-kappaB, which induces upregulation of TNFalpha and IL6 expression |
PubMed
|
|
nef
|
Stimulation of CD8+ T cells with HIV-1 Nef peptides upregulates perforin and TNF-alpha expression |
PubMed
|
|
nef
|
Nef inhibits ASK1/p38MAPK-dependent Mycobacterium tuberculosis-induced TNF-alpha production by inhibiting binding of ATF2 to the TNF-alpha promoter |
PubMed
|
|
nef
|
Mycobacterium tuberculosis-induced TNF-alpha production depends upon the Ets, Egr, Sp1, CRE or AP1 binding sites on the TNF-alpha promoter, whereas Nef-mediated promoter activation depends only on the CRE and AP1 binding sites |
PubMed
|
|
nef
|
HIV-1 Nef impairs the recruitment of TNF-alpha-positive compartments at the site of phagocytosis |
PubMed
|
|
nef
|
HIV-1 Nef significantly increases TNF-alpha release from Nef-treated homeostatic or inflamed mucosal cell lines. Nef abrogates the IFN-gamma-induced modulation of TNF-alpha secretion in these cells |
PubMed
|
|
nef
|
HIV-1 Nef and ALK show similar effects by increasing different cytokines/chemokines, such as IL-1beta, TNF-alpha, and RANTES, that may be relevant for HAD pathogenesis |
PubMed
|
|
nef
|
Expression of HIV-1 Nef in a CD4+ human T-cell hybridoma enhances the surface levels of the membrane-bound cytokines tumor necrosis factor (TNF) and LIGHT; the enhancement of TNF and LIGHT depends on the presence of a functional dileucine motif in Nef |
PubMed
|
|
nef
|
Intracisternal HIV-1 Nef injection upregulates levels of IL-6, TNF-alpha, and IFN-gamma in rat cerebrospinal fluid |
PubMed
|
|
nef
|
Nef-induced expression of TNF-alpha is observed in rat hippocampus grafted with Nef-transduced macrophages |
PubMed
|
|
nef
|
HIV-1 nef gene expression in human glial cells inhibits tumor necrosis factor alpha-induced apoptosis and promotes cell proliferation through the activation of MAPK and JNK |
PubMed
|
|
nef
|
HIV-1 Nef increases the level of tumor necrosis factor-alpha release from primary human-monocyte-derived macrophages (MDM) infected with HIV-1 |
PubMed
|
|
nef
|
The presence of recombinant HIV-1 Nef and ethanol upregulates the level of tumor necrosis factor alpha (TNF-alpha) production in primary human brain micro vascular endothelial cells |
PubMed
|
|
Pr55(Gag)
|
gag
|
The proportion of HIV-1 Gag-specific CD8+ T cells endowed with TNF-alpha+, IFN-gamma+, CD107A+, and MIP-1beta+ is significantly higher in patients with the lowest virus set point than those with the highest virus set point |
PubMed
|
|
gag
|
Stimulation of CD8+ T cells with HIV-1 Gag peptides upregulates perforin and TNF-alpha expression |
PubMed
|
|
gag
|
HIV-1 Gag virus-like particles expressed by recombinant baculoviruses activate human PBMC to release TNF-alpha in a dose and time dependent manner |
PubMed
|
|
gag
|
Stimulation of HIV-1 infected human adipocytes by TNF-alpha and IL-1beta increases the levels of HIV-1 Gag production |
PubMed
|
|
gag
|
The Matrix protein of HIV-1 Gag enhances the cytokine-induced production of TNF-alpha |
PubMed
|
|
Tat
|
tat
|
The gene expression of TNF is significantly upregulated in clade B Tat treated SK-N-MC neuroblastoma cells, but downregulated in clade C Tat treated SK-N-MC neuroblastoma cells |
PubMed
|
|
tat
|
Human microglia cells treated with HIV-1 clade C Tat show more significant upregulation of IL-6 and TNF-alpha, and higher NF-kappaB activation as compared to clade B Tat-treated cells |
PubMed
|
|
tat
|
HIV-1 Tat upregulates the production of cytokines, including TNF-alpha, IL-6, IL-10, IL-12, IFN-alpha1, and IFN-gamma, in human monocyte derived-dendritic cells and in primary human Muller glia |
PubMed
|
|
tat
|
HIV-1 Tat inhibitor didehydro-Cortistatin A (dCA), an analog of a natural steroidal alkaloid, potently inhibits Tat-mediated modulation of IL-1beta, TNF-alpha and MCP-1 |
PubMed
|
|
tat
|
Upregulation of TNF-alpha by HIV-1 Tat is implicated in the toxic effects of Tat, including neuronal death and astroglial dysfunction |
PubMed
|
|
tat
|
Upregulation of TNF-alpha by HIV-1 Tat leads to activation of NF-kappa B, leading to NF-kappa B induced activation of the HIV-1 LTR promoter |
PubMed
|
|
tat
|
HIV-1 Tat-induced release of TNF-alpha and IL-10 is TLR4-dependent in monocytes |
PubMed
|
|
tat
|
HIV-1 Tat-induced upregulation of PD-L1 on monocyte-derived dendritic cells involves a TNF-alpha-mediated mechanism through the TLR4 pathway |
PubMed
|
|
tat
|
Co-treatment with HIV-1 Tat, TNF-alpha, and ZVAD induces necroptosis in HT-29 cells |
PubMed
|
|
tat
|
Sulfated polymannuroguluronate (SPMG) significantly reverses HIV-1 Tat-induced release of pro-inflammatory cytokines such as TNF-alpha, IL-1beta, and IL-6 in THP-1 cells |
PubMed
|
|
tat
|
Exogenous Nef and TNF-alpha synergistically activate NF-kappaB and AP-1 resulting in enhancing HIV-1 Tat transactivation of the LTR and viral replication in both chronically infected promonocytic cells and acutely infected primary macrophages |
PubMed
|
|
tat
|
HIV-1 Tat significantly decreases TNF-alpha and IL-6 secretion but increases IL-4 levels in human hepatocellular carcinoma cells |
PubMed
|
|
tat
|
HIV-1 Tat inhibits CpG-A-induced secretion of TNF-alpha, IL-6, and IP-10 proteins in plasmacytoid dendritic cells and PBMCs |
PubMed
|
|
tat
|
HIV-1 Tat- and oxovanadate-treated microglial cells synergistically induce release of TNF-alpha and IL-1beta proteins, which involves CD45 and ERK1/2 signaling pathways |
PubMed
|
|
tat
|
LRRK2 is involved in HIV-1 Tat-induced cytokine TNF-alpha, IL-6, and MCP-1 expression in microglia cells |
PubMed
|
|
tat
|
HIV-1 Tat-mediated stimulation of TNF-alpha production through the activation of PKC beta(II) and delta isoforms requires p38 MAP kinase, ERK1/2 MAP kinase and NF-kappaB transcription factor in human macrophages |
PubMed
|
|
tat
|
HIV-1 Tat in combination with IFN-gamma and TNF-alpha increases CXCL10 mRNA and protein in human astrocytes through the activation of the p38, Jnk, and Akt signaling pathways and their downstream transcription factors, NF-kappaB and STAT-1alpha |
PubMed
|
|
tat
|
HIV-1 Tat from subtype E virus isolates inhibits TNF gene transcription and protein production in CD4(+) Jurkat T cells, and this repression is associated with the tryptophan at residue 32 of Tat |
PubMed
|
|
tat
|
Over-expression of PPARalpha or PPARgamma attenuates Tat-induced up-regulation of inflammatory mediators, such as interleukin (IL)-1beta, tumor necrosis factor-alpha, CCL2, and E-selectin |
PubMed
|
|
tat
|
Wild-type Tat but not Cys-22 and oxidized Tat induces CD1A-expressing monocyte-derived dendritic cells (MDDC) maturation and increases the production of cytokines TNF-alpha, IL-12, MIP-1alpha, and MIP-1beta |
PubMed
|
|
tat
|
Monocytes treated with HIV-1 clade B Tat show significant upregulation of proinflammatory cytokines, IL-6 and TNF-alpha, as compared to clade C Tat-treated cultures |
PubMed
|
|
tat
|
Recombinant CD40L synergizes with HIV-1 Tat to increase TNF-alpha release from primary human monocytes and microglia in an NF-kappaB-dependent manner. This synergism is attributed to a Tat-mediated up-regulation of CD40 |
PubMed
|
|
tat
|
HIV-1 Tat increases CXCL10 expression in IFN-gamma and TNF-alpha stimulated human astrocytes via NADPH oxidase |
PubMed
|
|
tat
|
Induction of TNF-alpha by HIV-1 Tat requires activation of NF-kappa B and also involves protein kinase A, tyrosine kinase, phospholipase C, protein kinase C, MAPK, and release of calcium from inositol 1,4,5-triphosphate receptor-regulated stores |
PubMed
|
|
tat
|
HIV-1 Tat interacts with TNF-alpha to induce monocyte metalloproteinase-9 production |
PubMed
|
|
tat
|
HIV-1 Tat interacts with TNF-alpha to potentiate NF-kappa B activation by downregulation of manganese-dependent superoxide dismutase (MnSOD) |
PubMed
|
|
tat
|
HIV-1 Tat inhibits TNF-alpha-induced repression of tumor necrosis factor receptor p55 and amplifies TNF-alpha activity in stably tat-transfected HeLa cells |
PubMed
|
|
tat
|
IL-1beta, TNF-alpha, and IFN-gamma synergize with HIV-1 Tat to promote in nude mice the development of angioproliferative Kaposi's sarcoma-like lesions |
PubMed
|
|
tat
|
HIV-1 Tat and TNF-alpha interact additively in upregulating IL-8 production |
PubMed
|
|
tat
|
HIV-1 Tat synergizes with TNF-alpha to induce the expression of adhesion molecules ICAM-1, VCAM-1 and ELAM-1 |
PubMed
|
|
tat
|
HIV-1 Tat synergizes with TNF-alpha to enhance IL-6 secretion and activate human central nervous system-derived endothelial cells |
PubMed
|
|
tat
|
HIV-1 Tat upregulates tumor necrosis factor alpha (TNF-alpha) expression, an effect mediated in U937 cells through the inhibition of CD26 |
PubMed
|
|
tat
|
HIV-1 Tat-induced calcium mobilization and TNF-alpha production in primary human monocytes are entirely regulated by DHP receptors |
PubMed
|
|
tat
|
HIV-1 Tat and TNF-alpha synergistically activate the adhesion of leukocytes to endothelial cells |
PubMed
|
|
tat
|
Treatment of T lymphocytes with IL-2, IL-6 and TNFalpha increases CDK9 and cyclin T1 protein levels, suggesting a mechanism for activation of HIV-1 Tat function and reactivation of HIV-1 in CD4+ T lymphocytes harboring a latent provirus |
PubMed
|
|
tat
|
HIV-1 Tat cooperates with Puralpha, cyclin T1, and CDK9 to activate the TNFalpha promoter and upregulate TNFalpha expression |
PubMed
|
|
Vpr
|
vpr
|
Vpr enhances TNF secretion from HIV infected MT4C5 & CD4+ T cells and is dependent on Vpr neosynthesis; i.e. results suggest that virion-incorporated Vpr is not sufficient to promote TNF secretion (in MT4C5 cells) |
PubMed
|
|
vpr
|
HIV-1 Vpr enhances HIV-1 replication in U1 cells by the induction of TNFalpha |
PubMed
|
|
vpr
|
HIV-1 Vpr expression results in increased IkappaB-alpha levels in the presence of TNF-alpha treatment in differentiated U937 cells |
PubMed
|
|
vpr
|
HIV-1 Vpr inhibits the NFkappaB signaling pathway in TNF-alpha treated cells and abolishes the phosphorylation of NFkappaB p65 subunit in response to such treatment |
PubMed
|
|
vpr
|
HIV-1 Vpr enhances TNF-alpha production in LPS-stimulated dendritic cells (DC). Vpr-induced TNF-alpha production in DC is through STAT1 activation |
PubMed
|
|
vpr
|
HIV-1 Vpr inhibits TNFalpha induced apoptosis in Jurkat cells |
PubMed
|
|
vpr
|
HIV-1 Vpr modulates expression of TNFalpha, increasing or suppressing TNFalpha expression through varying effects on NF-kappa B activity in different cell lines |
PubMed
|
|
Vpu
|
vpu
|
HIV-1 Vpu interferes with beta-TrCP to inhibit TNF-alpha-induced activation of NFkappaB |
PubMed
|
|
capsid
|
gag
|
Herpes simplex virus type 2-Infected monocyte-derived dendritic cells (MDDCs) produce TNF-alpha, which binds to its receptor TNF-R1 and upregulates the expression of CCR5 on cell surface, leading to enhance HIV-1 p24 release from MDDCs |
PubMed
|
|
gag
|
PLA-p24-loaded human monocyte-derived dendritic cells enhance the secretion of MIP-1beta, IL-6, IL-8, and TNF-alpha in comparison with PLA-loaded cells alone |
PubMed
|
|
gag
|
The increase of p24 in HIV-1 production from P. falciparum-infected red blood cells cocultured with CD4+ T cells is TNF-alpha dependent |
PubMed
|
|
gag
|
Unactivated memory CD4+ T cells infected by HIV-1 in the presence of IL-2 and IL-15 alone or IL-6/IL-7/TNF-alpha combination, upregulate granzyme B and HIV-1 CA production |
PubMed
|
|
matrix
|
gag
|
Exposure of TZM-bl-2 cells to HIV MA (p17) increases TNF (TNF-alpha) mRNA |
PubMed
|
|
gag
|
HIV-1 matrix protein colocalizes with syndecan-2, syndecan-4, and CD44v3 on activated CD4+ T cells to modulate TNF-alpha and IL2 production |
PubMed
|
|
gag
|
HIV-1 Matrix slightly enhances TNF-alpha and IFN-gamma secretion induced by IL-15 monocyte stimulation and counteracts IL-4 mediated inhibition in the production of these cytokines |
PubMed
|
|
gag
|
HIV-1 Matrix enhances the cytokine-induced production of TNF-alpha |
PubMed
|